Vivoryon Therapeutics N.V. (VVY.AS)
EUR 1.97
(0.71%)
EUR 1.97
(0.71%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 30.82 Million EUR | -1.75% |
| 2022 | 31.37 Million EUR | 27.97% |
| 2021 | 24.52 Million EUR | -17.58% |
| 2020 | 29.75 Million EUR | -35.13% |
| 2019 | 45.86 Million EUR | 1132829.84% |
| 2018 | 4048.00 EUR | -62.39% |
| 2017 | 10.76 Thousand EUR | -51.88% |
| 2016 | 22.36 Thousand EUR | 2.29% |
| 2015 | 21.86 Thousand EUR | 1.8% |
| 2014 | 21.48 Thousand EUR | -99.66% |
| 2013 | 6.37 Million EUR | -36.29% |
| 2012 | 10 Million EUR | -47.6% |
| 2011 | 19.09 Million EUR | 19.59% |
| 2010 | 15.96 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 16.99 Million EUR | 0.0% |
| 2023 FY | 30.82 Million EUR | -1.75% |
| 2023 Q2 | 45.35 Million EUR | 0.0% |
| 2023 Q4 | 30.82 Million EUR | 0.0% |
| 2022 Q4 | 31.37 Million EUR | 0.0% |
| 2022 Q2 | 31.74 Million EUR | 0.0% |
| 2022 FY | 31.37 Million EUR | 27.97% |
| 2021 FY | 24.52 Million EUR | -17.58% |
| 2021 Q2 | 23.04 Million EUR | 0.0% |
| 2021 Q4 | 24.52 Million EUR | 0.0% |
| 2020 FY | 29.75 Million EUR | -35.13% |
| 2020 Q4 | 29.75 Million EUR | 0.0% |
| 2020 Q2 | 37.9 Million EUR | 0.0% |
| 2019 Q4 | 45.86 Million EUR | 0.0% |
| 2019 Q2 | 9.26 Million EUR | 0.0% |
| 2019 FY | 45.86 Million EUR | 1132829.84% |
| 2018 Q2 | 7169.00 EUR | 0.0% |
| 2018 Q4 | 4048.00 EUR | 0.0% |
| 2018 FY | 4048.00 EUR | -62.39% |
| 2017 Q2 | 14.97 Thousand EUR | 0.0% |
| 2017 FY | 10.76 Thousand EUR | -51.88% |
| 2017 Q4 | 10.76 Thousand EUR | 0.0% |
| 2016 Q2 | 15.74 Thousand EUR | 0.0% |
| 2016 FY | 22.36 Thousand EUR | 2.29% |
| 2016 Q4 | 22.36 Thousand EUR | 0.0% |
| 2015 FY | 21.86 Thousand EUR | 1.8% |
| 2015 Q4 | 21.86 Thousand EUR | 0.0% |
| 2015 Q2 | 15.38 Thousand EUR | 0.0% |
| 2014 FY | 21.48 Thousand EUR | -99.66% |
| 2014 Q4 | 21.48 Thousand EUR | 0.0% |
| 2014 Q2 | 6604.00 EUR | 0.0% |
| 2013 Q4 | 6.37 Million EUR | 0.0% |
| 2013 FY | 6.37 Million EUR | -36.29% |
| 2012 FY | 10 Million EUR | -47.6% |
| 2011 FY | 19.09 Million EUR | 19.59% |
| 2010 FY | 15.96 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ABIONYX Pharma SA | 14.71 Million EUR | -109.579% |
| ABIVAX Société Anonyme | 327.06 Million EUR | 90.574% |
| Adocia SA | 24.95 Million EUR | -23.533% |
| Aelis Farma SA | 26.28 Million EUR | -17.305% |
| Biophytis S.A. | 11.93 Million EUR | -158.286% |
| Advicenne S.A. | 12.4 Million EUR | -148.481% |
| genOway Société anonyme | 31.84 Million EUR | 3.182% |
| IntegraGen SA | 8 Million EUR | -285.346% |
| Medesis Pharma S.A. | 1.92 Million EUR | -1500.397% |
| Neovacs S.A. | 47.53 Million EUR | 35.143% |
| NFL Biosciences SA | 3.97 Million EUR | -676.426% |
| Plant Advanced Technologies SA | 14.91 Million EUR | -106.727% |
| Quantum Genomics Société Anonyme | 3.74 Million EUR | -722.815% |
| Sensorion SA | 46.49 Million EUR | 33.693% |
| Theranexus Société Anonyme | 7.23 Million EUR | -325.948% |
| TME Pharma N.V. | 2.49 Million EUR | -1137.615% |
| Valbiotis SA | 33.24 Million EUR | 7.276% |
| TheraVet SA | 7.53 Million EUR | -309.188% |
| Valerio Therapeutics Société anonyme | 35.27 Million EUR | 12.601% |
| argenx SE | 4.11 Billion EUR | 99.25% |
| BioSenic S.A. | 9.55 Million EUR | -222.513% |
| Celyad Oncology SA | 16.28 Million EUR | -89.344% |
| DBV Technologies S.A. | 165.65 Million USD | 81.389% |
| Galapagos NV | 4.35 Billion EUR | 99.292% |
| Genfit S.A. | 173.87 Million EUR | 82.269% |
| GeNeuro SA | 6.31 Million EUR | -388.349% |
| Hyloris Pharmaceuticals SA | 47.68 Million EUR | 35.343% |
| Innate Pharma S.A. | 184.19 Million EUR | 83.263% |
| Inventiva S.A. | 69.13 Million EUR | 55.41% |
| MaaT Pharma SA | 42.93 Million EUR | 28.189% |
| MedinCell S.A. | 36.94 Million EUR | 16.561% |
| Nanobiotix S.A. | 93.89 Million EUR | 67.167% |
| Onward Medical N.V. | 43.62 Million EUR | 29.338% |
| Oryzon Genomics S.A. | 106.9 Million EUR | 71.161% |
| OSE Immunotherapeutics SA | 81.9 Million EUR | 62.358% |
| Oxurion NV | 6.55 Million EUR | -370.672% |
| Pharming Group N.V. | 426.33 Million EUR | 92.769% |
| Poxel S.A. | 4.82 Million EUR | -539.208% |
| GenSight Biologics S.A. | 9.08 Million EUR | -239.265% |
| Transgene SA | 45.21 Million EUR | 31.82% |
| Financière de Tubize SA | 1.92 Billion EUR | 98.395% |
| UCB SA | 15.53 Billion EUR | 99.802% |
| Valneva SE | 469.39 Million EUR | 93.432% |